about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Pfiz­er's $1.5B cuts; Bio­gen's $1.15B buy­out; As­traZeneca's $80B am­bi­tion; RNA start­up merg­er; and more

11 months ago
Weekly

Nu­va­tion Bio shares piv­otal Chi­na da­ta for can­cer drug from An­Heart buy­out

11 months ago
R&D
China

Oral drug shows promise in di­a­bet­ic mac­u­lar ede­ma as biotech touts an­ti-VEGF in­jec­tion al­ter­na­tive

11 months ago
R&D

With $5B in Chi­na sales, As­traZeneca dou­bles down on Chi­nese bio­phar­ma in­no­va­tion

11 months ago
China
Pharma

As­traZeneca counts on ‘dif­fi­cult-to-copy’ ther­a­pies for big 2030 goal and be­yond

11 months ago
R&D
Pharma

‘A new era of growth’: As­traZeneca aims for $80B rev­enue, 20 new drugs by 2030

11 months ago
Pharma

Mega start­up watch; In­ter­view with Sid­dhartha Mukher­jee; Track­ing We­govy’s long-term ef­fects; Bio­gen’s ALS flop; ...

12 months ago
Weekly

Ei­sai projects near-term Leqem­bi sales 'con­sid­er­ably high­er' than an­a­lyst fore­casts

Last year
Pharma

Up­dat­ed: France draws €2B+ re­search, man­u­fac­tur­ing in­vest­ment from Sanofi, Pfiz­er, As­traZeneca, GSK

Last year
Financing
Manufacturing

Top sto­ries from cell/gene ther­a­py con­fab; 2032 dead­line to de­cou­ple; Pa­tient death in Pfiz­er tri­al; and more

Last year
Weekly

Sanofi grabs a share of No­vavax's Covid vac­cine for $500M, eye­ing com­mer­cial­iza­tion, flu com­bi­na­tion

Last year
Deals
Pharma

In­novent says next-gen GLP-1 drug from Lil­ly beats top di­a­betes med in Phase 3 Chi­na study

Last year
R&D
China

Chiesi bets $160M on Gos­samer Bio’s make-or-break late-stage PAH drug

Last year
Deals

No­var­tis’ ra­dio­phar­ma gam­bit; Weight loss bat­tle plays out; Spark co-founder’s new start­up; Q1 earn­ings ...

Last year
Weekly

Up­dat­ed: Lil­ly boosts sales guid­ance by $2B, but GLP-1 sup­ply con­straints still a fo­cus

Last year
Pharma
Manufacturing

Lead drug from J&J and Ad­dex's 20-year col­lab­o­ra­tion flunks Phase 2 in epilep­sy

Last year
R&D

Bris­tol My­ers eyes ma­jor cuts; That $1B AI start­up; Phar­ma re­acts to Chi­na bill; Q1 earn­ings high­lights; and more

Last year
Weekly

De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Last year
R&D
China

Astel­las' Friedre­ich’s atax­ia gene ther­a­py cleared for clin­i­cal study af­ter ear­li­er ver­sion stum­bled

Last year
R&D
Cell/Gene Tx

AI drug dis­cov­ery start­up Benev­o­len­tAI cuts 30% of staff, clos­es US of­fice 

Last year
People
AI

No­var­tis will change CRO re­la­tion­ships ‘over time’ as Sen­ate bill tar­get­ing Chi­nese com­pa­nies looms

Last year
Pharma

Nvidi­a's biotech mo­ment; Re­gen­eron launch­es ven­ture arm; New GLP-1 play­er en­ters; Sanofi re­jigs can­cer pact, vac­cine ...

Last year
Weekly

Cerev­el notch­es Phase 3 Parkin­son's win ahead of Ab­b­Vie trans­ac­tion clos­ing

Last year
R&D

No­var­tis show­cas­es Ph3 da­ta for Fab­hal­ta in IgAN as FDA grants pri­or­i­ty re­view

Last year
R&D
Pharma
First page Previous page 123456 Next page Last page
A service from the Financial Times